- Co-ultramicronized PEA plus the flavonoid luteolin (branded Glialia in clinical research) is the most-studied version of “PEA stacking” in human trials, not a marketing combination
- A randomized placebo-controlled trial of PEA-LUT added to olfactory training reported better smell recovery than training plus placebo in patients with persistent post-COVID-19 olfactory loss, though both arms trained, so the gain cannot be separated from the training[1] [4][5]
- A 250-patient observational study with no control group reported gains in cognitive, motor, and pain measures in stroke patients using co-ultramicronized PEA-LUT during neurorehabilitation, which cannot be attributed to the product alone[2] [2]
- Most PEA-LUT research targets neuroinflammation, not the musculoskeletal pain conditions covered elsewhere on this site, so the evidence base is different from PEA alone
Anyone who has looked closely at PEA supplement labels has probably noticed luteolin showing up as a co-ingredient more often than any other compound. This isn’t a random pairing chosen to make a label look more sophisticated. Co-ultramicronized PEA plus luteolin, sometimes shortened to PEA-LUT, is a specific, patented formulation (marketed clinically as Glialia) that has its own separate body of randomized trials, distinct from the plain-PEA research covered in most of this site’s other articles.
What Luteolin Adds
Luteolin is a flavonoid antioxidant found in foods like celery, thyme, and green peppers. On its own it has modest anti-inflammatory and antioxidant activity. Combined with PEA at a 10:1 ratio by mass and co-processed into a single ultramicronized particle (rather than two separate compounds mixed together), the pairing improved behaviour in a mouse model of autism[3], though the publisher has since issued an Expression of Concern on that paper because duplicated western blot control bands meant one figure could not be confirmed [3][6]. The theory is that luteolin’s antioxidant action complements PEA’s mast-cell-calming action, and the co-micronization step improves how well both compounds are absorbed together.
The studied PEA plus luteolin product pairs 700 mg PEA with 70 mg luteolin, a 770 mg combined dose
700 mg + 70 mg
Trials in a systematic review used PEA 700 mg and luteolin 70 mg once daily for 90 days, usually with olfactory training.
770 mg combined
One trial gave ultramicronized PEA-LUT 770 mg plus olfactory training, or olfactory training with placebo, to 185 adults with post-COVID smell loss.
Twice daily, 24 weeks
A phase II trial gave 48 people with probable frontotemporal dementia co-ultramicronized PEA plus luteolin at 700 mg + 70 mg twice a day (25 people) or placebo (23 people) for 24 weeks.
Added on top of care
In 60 people with acute ischemic stroke having thrombolysis, PEALut (Glialia) was given in addition to standard care: PEA 700 mg + luteolin 70 mg in 10 mL, 10 mL twice daily, starting within 72 h.
When a label or trial says PEA plus luteolin, the dose and the evidence belong to the pair, not to PEA by itself.
Four sources describing the same ingredient pair at different schedules. Source: Bischoff et al., Current allergy and asthma reports 2024; Di Stadio et al., Current Neuropharmacology 2022; Assogna et al., Brain communications 2025; Bonzanino et al., Journal of clinical medicine 2024.
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
The Post-COVID Olfactory Research
The clearest recent clinical evidence for PEA-LUT comes from long COVID research. A multi-center, double-blinded, randomized, placebo-controlled trial gave patients with persistent smell loss (more than six months after testing negative for SARS-CoV-2) either daily ultramicronized PEA-LUT supplementation plus olfactory training, or olfactory training with a placebo. The PEA-LUT group showed meaningfully better recovery of smell function than the training-plus-placebo group[1]. This matters because it’s one of the few PEA-related trials targeting a specific, measurable, non-pain outcome (sense of smell) rather than a subjective pain score, which makes the result somewhat easier to verify objectively.
Research note: Even in published PEA-luteolin plus olfactory training trials, about 15% of treated patients do not reach a normal olfactory threshold and almost 5% have no recovery [12].
Not all smell-loss evidence agrees. In a 50-patient trial of olfactory training plus PEA-luteolin for post-infectious smell loss, smell scores improved, but clinically meaningful improvement did not differ significantly from training alone. A Cochrane review found only one randomised trial of PEA plus luteolin for persistent post-COVID smell loss, with 12 participants, and in a random-effects pooled analysis the confidence interval crossed no effect [5][8][9].
The Stroke Rehabilitation Data
The largest human dataset on PEA-LUT comes from a stroke recovery study. Researchers tracked 250 stroke patients undergoing neurorehabilitation, all treated for 60 days with the branded co-ultramicronized PEA-LUT preparation (700 mg PEA and 70 mg luteolin, taken sublingually twice daily) alongside their standard rehab therapy. Across neurological status, cognitive testing, spasticity, pain, and independence in daily activities, every measured index showed a statistically significant improvement from baseline to the 30-day mark[2]. This wasn’t a placebo-controlled trial in the strictest sense (patients were tracked against their own baseline, not a separate control arm), so it’s supportive rather than definitive evidence, but the sample size (250 patients) is unusually large for PEA research of any kind.
A separate 60-patient open-label trial compared PEALut plus alteplase with alteplase alone. Independence in daily living and disability improved more with PEALut, but the cognitive benefit was not tested against the control group because too few control patients could complete the tests, and Epitech Group, which makes Glialia, supplied the product [10].
Where This Research Doesn’t Apply
It’s worth being direct about scope: the strongest PEA-LUT evidence is in neuroinflammatory and neurological contexts, post-COVID olfactory loss, stroke rehabilitation, and animal work, with no published clinical trial of PEA in Alzheimer’s disease [7]. That’s a different evidence base from the chronic pain, fibromyalgia, and neuropathy research covered in most of this site’s PEA content, which typically uses PEA alone or at different micronization levels. Someone taking a PEA-luteolin combo product for joint or nerve pain is relying on PEA’s general anti-inflammatory mechanism, not on the specific trials described above, since none of those trials tested musculoskeletal pain outcomes.
A 48-person phase II trial in probable frontotemporal dementia gave PEA plus luteolin or placebo for 24 weeks. The primary outcome worsened by 0.53 points on PEA plus luteolin versus 1.39 on placebo, but there was no significant effect on MMSE, frontal assessment battery, neuropsychiatric inventory or frontal behavioural inventory scores, and the trial was partly funded by Epitech Group, the supplement’s maker [11].
Practical Notes
Co-ultramicronized PEA-LUT products are typically dosed lower on the PEA side than standalone PEA supplements aimed at pain (the clinical stroke research used 700 mg PEA plus 70 mg luteolin daily, split into two doses). Anyone considering a PEA-luteolin product specifically for its studied indications (post-viral smell loss, neurological recovery support) should look for products that specify co-ultramicronization, since that processing step is what the clinical trials actually used, not simply PEA and luteolin capsules combined without that manufacturing step.
FAQ
What does adding luteolin to PEA actually do?
Luteolin is an antioxidant flavonoid that, when co-ultramicronized with PEA at a 10:1 ratio, was reported to improve behaviour in one mouse model of autism[3], a paper now carrying a publisher Expression of Concern [3][6].
Is there human evidence for PEA-luteolin, or just animal studies?
Both. A placebo-controlled human trial in post-COVID smell loss and an uncontrolled 250-patient stroke rehabilitation study are two of the larger pieces of human evidence [2][1].
Does PEA-luteolin research apply to joint or nerve pain the way plain PEA research does?
Not directly. The PEA-LUT trials focus on neuroinflammatory conditions like post-viral olfactory loss and stroke recovery, not musculoskeletal pain.
Does the luteolin need to be co-ultramicronized with the PEA to match the research?
Yes, the clinical trials used a co-processed, single-particle formulation, not PEA and luteolin as two separately manufactured ingredients simply combined in one capsule.
References
- D’Ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner MJ, Di Stadio A. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial. Eur Rev Med Pharmacol Sci. 2021;25(11):4156-4162. PMID 34156697
- Caltagirone C, Cisari C, Schievano C, et al. Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man. Transl Stroke Res. 2016;7:54-69. PMID 26706245
- Cristiano C, et al. Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism. CNS Neurol Disord Drug Targets. 2016. PMID 27701827
- Arianna Di Stadio et al. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial. Current Neuropharmacology (2022). PMID 35450527
- Gellrich J et al. Palmitoylethanolamide and Luteolin for Postinfectious Olfactory Disorders: How Clinically Meaningful Is Its Effect?. ORL; journal for oto-rhino-laryngology and its related specialties (2024). PMID 38861957
- CNS neuroscience & therapeutics EXPRESSION OF CONCERN: Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism. CNS neuroscience & therapeutics (2024). PMID 39651688
- Assogna M et al. Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders. Biomolecules (2022). PMID 36009055
- O’Byrne L et al. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. The Cochrane database of systematic reviews (2022). PMID 36062970
- Capra AP et al. Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies. Biomedicines (2023). PMID 37626685
- Bonzanino M et al. PEALut in the Dietary Management of Patients with Acute Ischemic Stroke: A Prospective Randomized Controlled Clinical Trial. Journal of clinical medicine (2024). PMID 38256644
- Assogna M et al. Phase 2 study of palmitoylethanolamide combined with luteoline in frontotemporal dementia patients. Brain communications (2025). PMID 40046339
- Di Stadio A et al. Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?. Life (Basel, Switzerland) (2023). PMID 36676175
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.